{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:01:31Z","timestamp":1789052491652,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Taiho Pharmaceuticals Ltd.","award":["Grant Number:N\/A"],"award-info":[{"award-number":["Grant Number:N\/A"]}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1136\/ard-2022-223759","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T13:21:10Z","timestamp":1684761670000},"page":"1025-1034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Irreversible covalent Bruton's tyrosine kinase inhibitor, TAS5315 versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate: a randomised, double-blind, phase IIa trial"],"prefix":"10.1016","volume":"82","clinical-trial-number":[{"clinical-trial-number":"nct03605251","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03605251","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1111-8218","authenticated-orcid":false,"given":"Tsutomu","family":"Takeuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9210-9414","authenticated-orcid":false,"given":"Sakae","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2728-6198","authenticated-orcid":false,"given":"Mitsuru","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2022-223759_bib1","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1001\/jama.2022.0786","article-title":"What is rheumatoid arthritis?","volume":"327","author":"Smith","year":"2022","journal-title":"JAMA"},{"key":"10.1136\/ard-2022-223759_bib2","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"10.1136\/ard-2022-223759_bib3","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/nrrheum.2010.154","article-title":"The Japanese experience with biologic therapies for rheumatoid arthritis","volume":"6","author":"Takeuchi","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2022-223759_bib4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1136\/annrheumdis-2013-204020","article-title":"Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010","volume":"74","author":"Aga","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223759_bib5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13075-020-02380-z","article-title":"Long-term remission and biologic persistence rates: 12-Year real-world data","volume":"23","author":"Murray","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223759_bib6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR definition of difficult-to-treat rheumatoid arthritis","volume":"80","author":"Nagy","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223759_bib7","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1093\/rheumatology\/keab209","article-title":"Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice","volume":"60","author":"Takanashi","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223759_bib8","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1586\/1744666X.2014.926219","article-title":"The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences","volume":"10","author":"Keiserman","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1136\/ard-2022-223759_bib9","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","article-title":"Immunogenicity of Biologics in chronic inflammatory diseases: a systematic review","volume":"31","author":"Strand","year":"2017","journal-title":"BioDrugs"},{"key":"10.1136\/ard-2022-223759_bib10","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223759_bib11","author":"US Food and Drug Administration"},{"key":"10.1136\/ard-2022-223759_bib12","author":"European Medicines Agency"},{"key":"10.1136\/ard-2022-223759_bib13","first-page":"945","article-title":"Bruton's tyrosine kinase is involved in innate and adaptive immunity","volume":"20","author":"Brunner","year":"2005","journal-title":"Histol Histopathol"},{"key":"10.1136\/ard-2022-223759_bib14","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.cell.2007.12.037","article-title":"Tyrosine Kinases Btk and Tec regulate Osteoclast differentiation by linking RANK and ITAM signals","volume":"132","author":"Shinohara","year":"2008","journal-title":"Cell"},{"key":"10.1136\/ard-2022-223759_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41573-020-0082-8","article-title":"Kinase inhibition in autoimmunity and inflammation","volume":"20","author":"Zarrin","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1136\/ard-2022-223759_bib16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/annrheumdis-2015-eular.3864","article-title":"TAS5315, a novel Bruton's tyrosine kinase (BTK) inhibitor, demonstrates potent efficacy in mouse collagen-induced arthritis model","volume":"74","author":"Hosoi","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223759_bib17","first-page":"3095","article-title":"TAS5315, a novel Bruton's tyrosine kinase (BTK) inhibitor, demonstrates potent efficacy in an animal model of rheumatoid arthritis","volume":"67","author":"Hosoi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223759_bib18","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"Rheumatoid arthritis classification criteria: an American college of rheumatology\/European League against rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223759_bib19","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/annrheumdis-2019-eular.1887","article-title":"FRI0156 A phase 1, single and multiple ascending dose study of TAS5315 - a novel highly selective inhibitor of Bruton's tyrosine kinase - in healthy male volunteers","volume":"78","author":"Kumagai","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223759_bib20","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American college of rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223759_bib21","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/14397595.2017.1392057","article-title":"Efficacy and safety of Baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials","volume":"28","author":"Tanaka","year":"2018","journal-title":"Modern Rheumatology"},{"key":"10.1136\/ard-2022-223759_bib22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3899\/jrheum.190008","article-title":"Placebo response in rheumatoid arthritis clinical trials","volume":"47","author":"Bechman","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223759_bib23","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-223759_bib24","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/annrheumdis-2021-221807","article-title":"Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis","volume":"81","author":"Kerschbaumer","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223759_bib25","series-title":"TAS5315, a novel Bruton's tyrosine kinase inhibitor, demonstrates anti-inflammatory effect in autoimmune disease models","author":"Yoshiga","year":"2016"},{"key":"10.1136\/ard-2022-223759_bib26","series-title":"TAS5315, a novel Bruton's tyrosine kinase inhibitor, ameliorates inflammation and bone erosion in murine model of rheumatoid arthritis","author":"Yoshiga","year":"2017"},{"key":"10.1136\/ard-2022-223759_bib27","first-page":"261","article-title":"How to read Radiographs according to the sharp\/Van der Heijde method","volume":"27","author":"van der Heijde","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223759_bib28","first-page":"333","article-title":"Molecular basis and clinical application of biological markers of bone turnover","volume":"17","author":"Calvo","year":"1996","journal-title":"Endocrine Reviews"},{"key":"10.1136\/ard-2022-223759_bib29","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ctrv.2008.05.001","article-title":"Bone markers and their Prognostic value in metastatic bone disease: clinical evidence and future directions","volume":"34","author":"Coleman","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1136\/ard-2022-223759_bib30","doi-asserted-by":"crossref","first-page":"11526","DOI":"10.1074\/jbc.M708935200","article-title":"The Tec family tyrosine kinase Btk regulates RANKL-induced Osteoclast maturation","volume":"283","author":"Lee","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1136\/ard-2022-223759_bib31","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/jth.13651","article-title":"Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies","volume":"15","author":"Shatzel","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1136\/ard-2022-223759_bib32","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.41275","article-title":"Fenebrutinib versus placebo or Adalimumab in rheumatoid arthritis: a randomized, double-blind, phase II trial (ANDES study)","volume":"72","author":"Cohen","year":"2020","journal-title":"Arthritis Rheumatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724423388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724423388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2022-223759","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T03:50:29Z","timestamp":1739505029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724423388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0003496724423388"],"URL":"https:\/\/doi.org\/10.1136\/ard-2022-223759","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Irreversible covalent Bruton's tyrosine kinase inhibitor, TAS5315 versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate: a randomised, double-blind, phase IIa trial","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2022-223759","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 \u00a9 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}